Worth reading
44Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
108
Millions of yen (year-on-year increase in operating profit)Wording
Conditional
How definitive the wording is.Contents of this document
Presentation materials for financial resultsFirst quarter of the fiscal year ending May 20276 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥1,861 million+4.1%
Operating profit¥182 million+144.8%
Ordinary income¥191 million+161.9%
Net income¥142 million+147.5%
Gross Profit Margin30 %
Operating profit margin9.8 %
Selling, general and administrative expenses¥376 million
Results for the three months of the current quarterRevenue ¥1,861 million, operating income ¥182 million, ordinary income ¥191 million, net income ¥142 million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Pharmaceuticals business sales26.7
Chemicals business net sales25.5
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Performance remained strong even against the initial assumptions for the fiscal year.Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Higher revenue from the pharmaceutical business
- Higher revenue from the chemical business
- Improved cost ratio and higher gross profit following withdrawal from the health food business
- Lower selling, general and administrative expenses following withdrawal from the health food business
New initiatives
- Development of a chemical development centre (scheduled to open in July 2027)
- Development of the R&D environment through the introduction of a continuous pharmaceutical crystallisation unit
Segment results
Pharmaceuticals Business
Net Sales
¥1,068 million+21.7%
Operating profit
¥142 million
Year-on-year difference54
Chemicals Business
Net Sales
¥792 million+30.8%
Operating profit
¥41 million
Year-on-year difference33
Financial targets
Equity ratio: 45.6% (up 5.1 percentage points from the end of the previous fiscal year)Number of employees
205 People
Record dateEnd of May 2026
| Item | Details |
|---|---|
| Document type | Presentation materials for financial results |
| Fiscal Period Covered | First quarter of the fiscal year ending May 2027 |
| Net Sales | ¥1,861 million (YoY +4.1%) |
| Operating profit | ¥182 million (YoY +144.8%) |
| Ordinary income | ¥191 million (YoY +161.9%) |
| Net income | ¥142 million (YoY +147.5%) |
| Gross Profit Margin | 30 % |
| Operating profit margin | 9.8 % |
| Selling, general and administrative expenses | ¥376 million |
| Results for the three months of the current quarter | Revenue ¥1,861 million, operating income ¥182 million, ordinary income ¥191 million, net income ¥142 million |
| Progress against full-year forecast | Pharmaceuticals business sales 26.7 / Chemicals business net sales 25.5 |
| Self-assessment against the plan | Performance remained strong even against the initial assumptions for the fiscal year. |
| Segment results | Pharmaceuticals Business Net Sales ¥1,068 million (YoY +21.7%) / Operating profit ¥142 million / Chemicals Business Net Sales ¥792 million (YoY +30.8%) / Operating profit ¥41 million |
| Breakdown of Factors Affecting the Change | Higher revenue from the pharmaceutical business, Higher revenue from the chemical business, Improved cost ratio and higher gross profit following withdrawal from the health food business, Lower selling, general and administrative expenses following withdrawal from the health food business |
| Number of employees | 205 People |
| Financial targets | Equity ratio: 45.6% (up 5.1 percentage points from the end of the previous fiscal year) |
| New initiatives | Development of a chemical development centre (scheduled to open in July 2027), Development of the R&D environment through the introduction of a continuous pharmaceutical crystallisation unit |
Items this document does not state (14)
Full-year earnings forecastKey KPIsUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In addition to higher revenue from the pharmaceutical and chemical businesses, the withdrawal from the health food business improved the cost ratio and reduced selling, general and administrative expenses.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.